<DOC>
	<DOCNO>NCT01465503</DOCNO>
	<brief_summary>Bleeding occur percutaneous coronary intervention ( PCI emerge one common complication PCI adversely affect in-hospital , short- long-term outcome.As bivalirudin prove effectiveness decrease haemorrhagic event PCI , administration may advocate subject deem high risk bleeding.Objective present trial compare safety effectiveness procedural use bivalirudin comparison unfractionated heparin ( UFH ) patient undergo PCI deem high risk procedural bleeding .</brief_summary>
	<brief_title>Novel Approaches Preventing Limiting Events III Trial ( NAPLES III ) : Bivalirudin High-risk Bleeding Patients</brief_title>
	<detailed_description>Antithrombotic antiplatelet therapy focus extensive clinical investigation past 2 decade . In PCI setting therapy inhibit coagulation primary hemostasis may limit ischaemic event rate , associate increase risk bleeding . Retrospective registry data indicate haemorrhage associate mortality patient undergo PCI , emphasize potential importance minimize bleeding , well ischemic event , bleed emerge one common complication PCI . Major bleed blood transfusion strongly associate increased rate in-hospital late mortality , MI repeat revascularization PCI . Also minor bleeding , although represent complication significantly less dangerous major haemorrhage , associate prolonged hospitalization , increase cost adversely affect short- long-term outcome . UFH commonly use anticoagulant drug PCI . Bleeding event PCI may part due use drug . Bivalirudin ( The Medicine 's Co. , Parsippany , NJ ) synthetic direct thrombin inhibitor approve patient stable unstable coronary syndrome undergo PCI . Favourable property bivalirudin may minimize bleeding . Several clinical procedural factor evaluate identify patient expose high risk hemorrhage . Nikolsky et al . develop risk score ( validated REPLACE-1 REPLACE-2 data ) base clinical variable useful predict incidence major peri-procedural bleeding contemporary PCI use femoral approach . The clinical variable consider algorithm age &gt; 55 year ( integer score 4 every 10 year 55 ) , female gender ( integer score 3 ) , eGFR &lt; 60 ml/min/1.73 m2 ( integer score 2 ) , pre-existing anaemia ( integer score 2 ) , administration low-molecular weight heparin within 48 hour ( integer score 2 ) . Global risk score 0-1 anticipated major bleed rate 1.3 % ; risk score 2-6 associated 1.8 % risk major bleeding ; risk score 7-9 associated 2.7 % risk major bleeding , whereas risk score &gt; =10 associate 5 % rate major bleeding . Our hypothesis bivalirudin , compare UFH , may provide significant benefit term bleed select population patient deem high risk bleeding . Our aim thus prove , double-centres , randomize , blind controlled trial enrol patient undergo PCI via femoral approach , efficacy term haemorrhagic event , secondarily , effectiveness safety bivalirudin mean study drug v UFH . Sample size estimation : high risk population expect rate major minor bleed &gt; 5 % UFH group vs 3 % event rate bivalirudin group . Aiming 0.05 alpha 0.80 power , total 662 patient need enrol ( 331 patient per group ) . This increase 25 % ( leading total 830 patient ) considerable uncertainty expect end-point rate .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<criteria>• Male female able understand sign witness informed consent Age ≥ 18 y Patients stable ( CCS 14 ) unstable angina pectoris ( recent anginal episode occur &gt; 48 hour procedure ) document silent ischemia Stable Hemodynamic condition ( systolic BP &gt; 100 HR &gt; 40 &lt; 100 ) . No clinical ECG change suggestive ongoing acute recent ( &lt; 48 hour ) myocardial infarction . Bleeding risk score ≥ 10 Procedure plan via femoral approach Double antiplatelet therapy . 4.2.2 Angiographic inclusion criterion • Angiographic evidence de novo lesion &gt; 50 % require intervention • Female sex childbearing potential Age &lt; 18 year Ongoing recent episode ( &lt; 48 hour ) unstable coronary artery disease ( include STelevation nonSTelevation acute coronary syndrome ) Chronic kidney disease ( estimate glomerular filtration rate &lt; 30mL/min/1.73 m2 ) . Ongoing serious bleed bleed diathesis Previous stroke last 6 month Platelet count ≤100,00 per mm3 History heparin inducedthrombocytopenia Known hypersensitivity contraindication aspirin , heparin , clopidogrel , sensitivity contrast adequately premedicated . Hemodynamic instability ( systolic blood pressure &lt; 100 mm Hg ; heart rate &lt; 40 bpm &gt; 100 bpm ; complex ventricular arrhythmia ; AV block ) require balloon counterpulsation inotropic support . The patient simultaneously participate another device drug study . Patient must complete followup phase previous study least 30 day prior enrolment study . Positive clinical history intracranial neoplasia , AV malformation , aneurysm . INR ≥ 2.0 prothrombin time 1.2 time upper limit normality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>bleeding</keyword>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>heparin</keyword>
	<keyword>bivalirudin</keyword>
</DOC>